Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | ELOVL1 | Q9BW60 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DCK | P27707 | 8/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423914 | 0.87 | PDE10A (0.37) | GPR119PDE10AEP300 | |
| SCHEMBL30494520 | 0.87 | ELOVL1 (0.34) | GPR119ELOVL1CYP2C19DCK | |
| SCHEMBL24253951 | 0.87 | PDE10A (0.37) | GPR119PDE10AEP300 | |
| SCHEMBL24253764 | 0.87 | ELOVL1 (0.34) | GPR119ELOVL1CYP2C19DCK | |
| SCHEMBL30423574 | 0.87 | ELOVL1 (0.34) | GPR119ELOVL1CYP2C19DCK | |
| SCHEMBL24253653 | 0.85 | PDE10A (0.41) | PDE10AEP300 | |
| SCHEMBL30423903 | 0.85 | PDE10A (0.41) | PDE10AEP300 | |
| SCHEMBL24253644 | 0.83 | ELOVL1 (0.41) | ELOVL1CYP2C19 | |
| SCHEMBL30424148 | 0.83 | ELOVL1 (0.41) | ELOVL1CYP2C19 | |
| SCHEMBL24253647 | 0.83 | EP300 (0.35) | PDE10AEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196478-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2023-06-21 | — | — | EP | claimed |
| CN-116157404-A | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | 诺华股份有限公司 | 2023-05-23 | — | — | CN | claimed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| EP-4196478-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| CN-116157404-A | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | 诺华股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | GPR119 418/4885ELOVL1 4619/4885CYP2C19 33/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | GPR119 418/4885ELOVL1 4619/4885CYP2C19 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.